#nephtwitter — Public Fediverse posts

17/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Research needed to ⬇️ tox while maintaining efficacy

❓Alternative dosing strategies (incl. dose breaks)
❓Effects of dose ⬇️ on pt outcomes
❓Effects of reduced ▶️ dose on pt outcomes

15/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢Pt w mRCC
🔸Initiated tx w pembro + lenva
🔹Developed G3 diarrhea
🔸Lenva withheld & anti-diarrheal treatment initiated 🔹Diarrhea now resolved.

🟢What next step is best for the pt?

14/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

Effective tox mgmt ➡️optimize pt outcomes✅

🩺 Mgmt strategies include...🩺
🔹Prevention
🔸Monitor BP, urine protein, thyroid & liver function
🔹Dose modification (⏸️⬇️🛑)
🔸Supportive care

13/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
🔸Fatigue
🔹Pruritus
🔸Diarrhea
🔹Rash
🔸Nausea

12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite

11/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

Some AEs attributable to either drug
These🔂overlapping tox can complicate pt mgmt

10/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢Which of the following is an AE that is commonly observed with both ICIs and TKIs?

7/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢Which of the following is a characteristic feature of the most common toxicities associated with anti-angiogenic therapies?

6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell

✳️Dual ICI combo (ipi + nivo) also approved tx option

💎#CheckMate214 - ipi + nivo vs sunitinib
✅Longest follow-up in frontline RCC (>5 years)
✅OS and PFS favor combo tx in int/poor risk pts

3/ #TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter

🟢 Which of the following TKI/IO combo regimens is 🚫NOT approved by the FDA for the frontline mgmt of #RenalCell carcinoma?

2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 http://bit.ly/3VDaK81

✳️The critical elements👇

1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗http://bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty?